Determining the optimal timing of disease-modifying therapies for neurodegenerative disorders will necessitate identification of when the underlying pathobiological process becomes active, well in advance of the point at which clinical manifestions appear. Phenoconversion, the emergence of clinically manifest syndomes,...
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
Summary DNA methylation (DNAm)-based tools are predominantly developed in European ancestry, high-income populations, raising questions on their applicability in diverse and rural settings. To evaluate these tools in a sub-Saharan African low-income context, we analyzed genome-wide DNAm data from 49 dried blood spot sa...
Beryl C. Zhuang, Chaini Konwar, Iliana V. Kohler et al.· iScience· 0 citations
BACKGROUND AND OBJECTIVES
Histopathologic staging of Alzheimer disease has led to validation of imaging techniques that guide diagnosis and treatment. We previously constructed preliminary phases of the sequential progression of TDP-43 and tau to guide similar efforts in behavioral-variant frontotemporal dementia (bvFT...
R. Magee, Sharon X. Xie, DT Ohm et al.· Neurology· 1 citation
A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
M. Benatar, SJ Barmada, Gregory A. Jicha et al.· JAMA Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
